Media inquiries only, please contact Andrea Hofelich via email or phone, 202-827-2078.
The National Pharmaceutical Council, a health policy research organization based in Washington, D.C., today welcomed four biopharmaceutical companies to its growing membership roster. They include AstraZeneca, Gilead Sciences, Horizon Pharma plc. and Spark Therapeutics, Inc.
National Pharmaceutical Council Launches Going Below the Surface, a Research Initiative to Explore the Different Dimensions of Health Care Spending ( )
The National Pharmaceutical Council launched Going Below the Surface—a new research-first initiative intended to engage stakeholders across the health care ecosystem in conversation about what’s driving health care spending in the United States and how we can spend more effectively.
NPC announced that Mark J. Nagy, Vice President, Global Patient Outcomes and Real World Evidence, Eli Lilly and Company, has been elected chairman of NPC’s Board of Directors for 2017-2018. NPC’s Board of Directors also elected other members to its executive committee.
Study Finds Disconnect Between Employers and PBMs Over Transparency, Rebates, Value and Contracts ( )
According to a study conducted by Benfield, a division of Gallagher Benefit Services, on behalf of the National Pharmaceutical Council, there is a disconnect between the important role employers believe their pharmacy benefit managers play in helping to manage prescription drug benefits and employers’ perceptions of the overall value they are getting from their PBMs. Findings indicate that this disconnect is rooted in employer concerns about transparency, contract complexity, rebates and focus on value.
Accountable Care Organizations Have Made Progress Toward Optimizing Medication Use, But Still Face Challenges ( )
The use of medications is an important part of helping accountable care organizations (ACOs) meet quality measures and improve patient outcomes, but a new study shows that ACOs still face barriers to optimizing medication use across their networks.
The National Pharmaceutical Council and Discern Health today released a white paper analyzing the gaps in accountable care quality measure sets for cancer, which can lead to missed opportunities to spot problems or improve care.